DTT (Dithiothreitol) Clinical Trials

Size	Price	Qty
500mg	USD 147
1g	USD 197

Clinical Trials

Multiple clinical trials evaluate therapeutic, diagnostic, and rehabilitative interventions across diverse indications, including breast cancer, stroke-related hemiplegia, vestibular schwannoma, autism spectrum disorder, mild cognitive impairment, opioid use disorder, and Parkinson's disease. Ranging from Phase 3 to non-interventional or unclassified protocols, these studies are sponsored by major academic medical centers and healthcare networks such as Karolinska University Hospital, King's College Hospital NHS Trust, and the University of California, Los Angeles. Recruitment statuses encompass completed, active, recruiting, and active-not-recruiting protocols.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07660978	NOT_YET_RECRUITING	PARKINSON DISEASE (Disorder); Parkinson Disease (PD); Parkinson s Disease; Postural Instability; Postural Instability Gait Disorders; Gait Disorders; Cognitive Dysfunction, Cognitive Disorder	Bezmialem Vakif University	2026-06-20
NCT03883139	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder	University of California, Los Angeles	2021-03-01
NCT07209982	COMPLETED	Hemiplegia; Hemiplegia Following Ischemic Stroke; Stroke	University of Lahore	2025-01-15
NCT04057976	COMPLETED	Vestibular Schwannoma	King's College Hospital NHS Trust	2019-06-27
NCT05730790	UNKNOWN	Mild Cognitive Impairment	Tan Tock Seng Hospital	2021-03-31
NCT06255119	Completed	Opioid Use Disorder	3D Therapy LLC	2022-10-18	Not Applicable
NCT04057976	Recruiting	Vestibular Schwannoma	King''s College Hospital NHS Trust\|Guy''s and St Thomas'' NHS Foundation Trust	2019-06-27	Not Applicable
NCT01751698	COMPLETED	Autism	University of California, Los Angeles	2013-01
NCT00798070	ACTIVE_NOT_RECRUITING	Breast Cancer	Karolinska University Hospital	2007-02	PHASE3

(data from https://clinicaltrials.gov, updated on 2026-06-25)

Check the DTT (Dithiothreitol) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a small-molecule redox reagent, dithiothreitol reduces intermolecular and intramolecular disulfide bonds within biological macromolecules through thiol-disulfide exchange, thereby disrupting protein tertiary conformation and downstream biochemical activity. This structural denaturation alters redox-sensitive signaling pathways and destabilizes functional protein networks, offering a mechanistic foundation for targeting aberrant protein structures in clinical trial contexts such as breast cancer.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).